canis - Articles
Verdinexor
Synonym(s): Laverdia-CA1®
Introduction
Name
- Verdinexor (Laverdia-CA1®).
Class of drug
- Antineoplastic.
Description
Chemical name
- (Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N’-(pyridin-2-yl)prop-2-enehydrazide.
- KPT-335, KY9, ALI-335.
Molecular formula
- C18H12F6N6O.
Molecular weight
- 442.3.
Physical properties
- Immediate release, film coated tablets.
Storage requirements
- Store at controlled room temperature 20-25°C/68-77°F.
Uses
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Administration
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Pharmacokinetics
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Precautions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Adverse reactions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Further Reading
Publications
Refereed papers
- Recent references from PubMed and VetMedResource.
- Mealey K L, Burke N S (2023) Assessment of verdinexor as a canine P-glycoprotein substrate. Vet Pharm & Ther 46 (4), 264-267 PubMed.
- Breitbach J T, Louke D S, Tobin S J, Watts M R et al (2021) The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines. Vet Comp Onc 19 (2), 362-373 PubMed.
- Sadowski A R, Gardner H L, Borgatti A, Wilson et al (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14, 1-7 PubMed.
- London C, Bernabe L F, Barnard S, Kisseberth W, et al (2013) Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) verdinexor (KPT-335) in spontaneous canine cancer: results of phase I and phase II clinical trials. Blood, 122 (21), 5149 PubMed.